Immortagen Inc., a University of Iowa spinoff venture, announced it has completed its Series A equity financing.

Immortagen is a women's cancer company that is developing genetic analysis tools for personalized medicine. The proprietary tools will assist pharmaceutical and diagnostics companies in interpreting next-generation genetic data and guide clinical trial design and recruitment.

Viewpoint Molecular Targeting recently received an invitation to present at the National Council of Entrepreneurial Tech Transfer (NCET2) University Startups Demo Day on Sept. 20 in Washington, D.C.

This morning, Gov. Terry Branstad, Lt. Gov. Kim Reynolds, Executive Director of the Governor's STEM (Science, Technology, Engineering and Mathematics) Advisory Council Jeff Weld, and Waukee second-grade teacher Heather Anderson, accompanied by five of her students, discussed results from the 2015-2016 independent evaluation that measures the success of the STEM Council's efforts to advance STEM education and economic development across Iowa.

Highlights of the 306-page Iowa STEM evaluation include:

In the early 2000s, cystic fibrosis researchers were frustrated with available mouse models of the disease. The mice carried the mutant version of the cystic fibrosis transmembrane conductance regulator (CFTR) gene that causes the disease in people, but the animals didn’t develop the mucus-coated lungs, coughing, or breathing difficulty observed in human patients. Researchers at the University of Iowa (UI) thought they might have a solution—genetically modified miniature pigs.